L. Michael Glodé

Dr. Glode has been a key clinical investigator in a number of urologic oncology trials and was co-PI on Phase I, II, and III studies that led to the FDA approval of leuprolide. He continues to serve as a scientific advisor to a number of pharmaceutical companies in the urologic oncology space, including Jansen, Dendreon, Medivation, and Exelixis among others.